This FAQ explains how aseptic processing, contamination control, and validation protect patients amid sterile injectable failures.
|Articles|November 11, 2022
Cytiva Opens Cell Culture Center of Excellence
Author(s)BioPharm International Editors
The new Massachusetts facility will strengthen Cytiva’s cell culture services.
Advertisement
Cytiva announced on Nov. 9, 2022 that it has opened a new Cell Culture Center of Excellence at its Marlborough, Massachusetts location. The center will provide expanded cell culture media development capabilities and new cell line development services, aligning with the company’s long term growth strategy.
The facility is 11,500 ft2 and will be run by experiences scientific teams and staff dedicated to transforming the future of process development, according to a company press release. Cytiva now provides a comprehensive approach to supporting customers working in early process development.
“Our Cell Culture Center of Excellence combines our scientific expertise with the latest technology. Our tailored solutions enable customers to bring a wide range of molecules from discovery to delivery – smarter and faster,” said Amanda Halford, vice-president, BioProcess, Cytiva, in the release.
Source:
Advertisement
Related to this article
Bimekizumab-bkzx (Bimzelx) produced ACR50 joint responses in 54.9% of psoriatic arthritis patients at week 24 vs 43.8% with risankizumab.
VG801 gene therapy improved vision through 12 months in a Stargardt disease trial as VeonGen aligned with FDA on its pivotal phase 3 design.
Matt Trupo, Richard Jaenisch, and Brian Drapeau explore how AI advances biological insights, drug-target discovery, and supply chains.
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
Aldevron and IDT added PE Ultra prime editor mRNA and 6 ABE8e base editor mRNAs to help researchers edit DNA without double-strand breaks.
In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
4
Beam's Risto-cel Meets Primary Endpoint in Sickle Cell Trial
5